All
Research advances may target varicose vein therapies
July 1st 2012A single intracellular molecule, activator protein-1 (AP-1), appears to initiate the signaling cascade for vascular remodeling that results in varicose veins. Assuming that these findings on the mechanisms of the disease in a mouse model translate into humans, they offer new targets for therapeutic intervention that go beyond current surgical options, a researcher says.
Topical vitamin D analogues partnered with corticosteroid for psoriasis enhances efficacy
July 1st 2012Use of combination therapy as a means to improve efficacy and minimize toxicity is a well-accepted principle in medicine. As it applies to the management of psoriasis, the results of multiple studies support the value of combination topical therapy with a vitamin D analogue and corticosteroid, said two speakers at the 2012 Winter Clinical Dermatology Conference.
Dermatology Times, Digital Edition, June 2012
June 1st 2012Sun Exposure : Despite increased warnings, people continue to tan at an alarming rate. Why aren’t they receiving the message? Lessons in Lyme disease : Researchers plan clinical trial to investigate treatment for post-infection chronic inflammation Clinical Dermatology : Newly approved microwave device zaps hyperhidrosis Cosmetic Dermatology : Tips and tricks to manage hair growth Cutaneous Oncology : SLNB is appropriate for some thin melanomas Practice Management : Stop embezzlement in your practice before it starts Special Report : Psychodermatology
PDT/HAL delivers rejuvenation without significant downtime
June 1st 2012A randomized, split-face, controlled study has shown that photodynamic treatment using hexyl aminolevulinate HCl (HAL; Allumera, Photocure) and multiple laser and light sources is safe, well tolerated and effective for photorejuvenation, says Sabrina Fabi, M.D.
Dermatology is at a trisection of science, art and policy that warrants further study
June 1st 2012The medical world is changing; this is fact. Exactly how these changes will translate into practice and affect dermatology is unclear. So unclear, in fact, that many are scrambling to address issues that may or may not be relevant as the model for healthcare delivery is debated on national, state and local levels. This leaves dermatology at the apex of a trisection between science, art and policy that warrants further inquiry.
Ensure your NPs, PAs are being used optimally, legally
June 1st 2012Healthcare issues are heating up. Take, for example, recovery audit contractors (RACs), Z-Picks (bounty hunters for the commercial carriers), Obamacare being challenged in the U.S. Supreme Court, the Office of Inspector General (OIG) "hit list" targeting providers for overpayments, fraud and abuse allegations, and 5010 playing havoc with our claims processing system. What else can go wrong?
Three years after Accutane's withdrawal, derms discuss current prescribing practices
June 1st 2012Three years after Roche pulled Accutane off the market, On Call wondered whether dermatologists were still using isotretinoin, whether they see problems from these portended side effects, and whether patients and their parents are as concerned about the medication as they used to be.
New microwave-based device zaps hyperhidrosis
June 1st 2012"A new microwave-based device is achieving long-lasting results in treating hyperhidrosis, said Suzanne L. Kilmer, M.D., at this year's MauiDerm: Advances in Cosmetic and Medical Dermatology. Approved for primary axillary hyperhidrosis in January 2011, the miraDry System (Miramar Labs) essentially kills targeted sweat glands with microwave energy."
Yale dermatologist blends creativity and science, personally and professionally
June 1st 2012It was the late 1980s, and David J. Leffell, M.D., set out to launch a dermatologic surgery and oncology program at Yale University School of Medicine. His aim: To marry advanced diagnostic and treatment techniques in cutaneous oncology with clinical research.
Pegylated, standard interferon retain relevance in some melanoma cases
June 1st 2012Interferon and the recently Food and Drug Administration-approved pegylated interferon remain relevant adjuvant therapies for patients with lymph node-positive melanoma, even in light of advances with CTLA4 blockade and BRAF-targeted therapies for late-stage disease, says Vernon K. Sondak, M.D., chairman, department of cutaneous oncology, Moffitt Cancer Center, Tampa, Fla.
Suspected melanonychia in pediatric patients can confound physicians
June 1st 2012Differentiating benign nail pigmentations such as melanonychia from either nail or nail matrix melanoma is especially difficult in children because pediatric lesions present differently than they do in adults, according to Antonella Tosti, M.D., professor of the department of dermatology and cutaneous surgery, University of Miami Miller School of Medicine.
Tips and tricks to help prevent embezzlement in your practice
June 1st 2012Motivation, opportunity and rationalization. This may sound like the title of a new James Bond film, but in reality, it's the triad of factors that provides fertile ground for the internal fraud that is an all-too-common occurrence in dermatologists' offices. A recent survey by the Medical Group Management Association (MGMA) revealed that 82.8 percent of managers had worked in a practice that experienced embezzlement.